<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090738</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0941</org_study_id>
    <nct_id>NCT02090738</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori infection is associated with several gastric diseases, including
      gastritis, peptic and duodenal ulcers, gastric carcinoma and MALToma. In 1994, the WHO
      classified the organism as a type 1 carcinogen. In order to eradicate H. pylori, at least two
      antibiotics and a proton pump inhibitor are used as a standard therapy regimen. Emerging
      antibiotic resistance to metronidazole or clarithromycin, however, has made successful
      treatment of infection progressively more difficult, with the success rate of standard triple
      therapy now at 70%, well below the 80% required for treatment of infectious diseases.
      Therefore, new treatment regimen is required for successful H. pylori eradication.

      On the other hands, many in vitro studies revealed that bacterial carbonic anhydrase in H.
      pylori has an important role for surviving of H. pylori in the stomach. It was demonstrated
      that mutation of carbonic anhydrase affected survival of H. pylori. The investigators
      therefore expected that administration of carbonic anhydrase inhibitor (acetazolamide) with
      standard H. pylori eradication regimen would increase the eradication rate. Here, the
      investigators aim to evaluate the efficacy of standard triple regimen plus acetazolamide for
      H. pylori eradication.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>1 month from the eradication therapy</time_frame>
    <description>H. pylori eradication rate will be assessed by urea breath test after eradication therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide group</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
    <other_name>Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days</other_name>
    <other_name>Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days</other_name>
    <other_name>Clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg, bid, for 7 days</other_name>
    <other_name>Acetazolamide (Diamox®, SK Chemicals Co. Ltd., Suwon, Korea) 250mg, bid, for 7 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard regimen group</intervention_name>
    <arm_group_label>Arm2</arm_group_label>
    <other_name>Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days</other_name>
    <other_name>Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days</other_name>
    <other_name>Clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg, bid, for 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age, between 19 and 70

          2. H. pylori infected patients

        Exclusion Criteria:

          1. Previous history of H. pylori eradication

          2. Previous history of gastrectomy

          3. Administration of PPI, H2 blocker, antibiotics, or bismuth within 1 month prior to
             enrollment

          4. Allergy to sulfonamide

          5. Electrolyte imbalance

          6. Adrenal insufficiency

          7. Pregnancy or breast milk feeding

          8. Active infection

          9. Severe hepatic dysfunction

         10. Severe renal dysfunction

         11. Severe bone marrow dysfunction

         12. Significant neurologic or psychologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>severnace Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>April 27, 2014</last_update_submitted>
  <last_update_submitted_qc>April 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

